EPEmily Poehlein

Emily Poehlein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emily Poehlein has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Cynthia L. Green

    Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA

    4 shared publications
  • Trevor A. Lentz

    Duke University School of Medicine, Department of Population Health Sciences, 215 Morris Street, Durham, NC 27701, USA; Duke University School of Medicine, Department of Orthopaedic Surgery, 311 Trent Drive, Durham, NC 27710, USA; Duke Clinical Research Institute, 300 W. Morgan Street, Durham, NC 27701, USA; Duke Margolis Institute for Health Policy, 230 Science Drive, Durham, NC 27708, USA

    3 shared publications
  • Angela Profeta

    CityMD Summit Med Grp, New York, NY USA

    2 shared publications
  • Chris Gainus

    CityMD Summit Med Grp, New York, NY USA

    2 shared publications
  • Daniel Frogel

    CityMD Summit Med Grp, New York, NY USA

    2 shared publications
  • Hui-Jie Lee

    Department of Biostatistics and Bioinformatics Duke University Durham North Carolina USA

    2 shared publications

Latest Publications

  • Open Access

    Patient-reported outcomes of a comprehensive management program for osteoarthritis of the hip and knee

    by Trevor A. Lentz, Preston Roundy, Emily Poehlein, Cynthia L. Green, Richard C. Mather, William Jiranek


  • Open Access

    Integration of Mindfulness and Acupuncture After Spine Surgery: Protocol for a Randomized Acceptability and Feasibility Trial

    by Trevor A Lentz, Laura S Porter, Lewis McGarvey, Cassandra Rhodes, Brett Rocos, Tina Gremore, Emily K Reinke, Stephanie A Eucker, Cynthia L Green, Emily Poehlein, et al.

    Background: Spine surgery is increasingly common in the United States, contributing substantially to spine-related health care costs. While many patients benefit, up to 25% experience chronic postsurgical pain, and the procedure is linked to high rates of opioid misuse. Key risk factors for persistent pain and opioid use include poorly controlled early postsurgical pain, high pain-sensitivity, and poor pain-coping. Clinical guidelines recommend multimodal treatment to address these risks, but such approaches are not well studied or widely implemented. Combining two safe and effective nonpharmacologic treatments, specifically mindfulness and acupuncture that target these factors, has the potential to improve postsurgical recovery and reduce the incidence of chronic pain and opioid use. Objective: This paper describes the study protocol for the Integrating Mindfulness and Acupuncture after Spine Surgery (I-MASS), which is a single-site, 2-arm randomized controlled trial that will assess the feasibility and acceptability of a novel multicomponent program integrating mindfulness delivered via a mobile app, acupuncture, and education for patients undergoing single-level spine surgery. Methods: A total of 50 participants will be randomized 1:1 to receive (1) mindfulness and acupuncture (ie, I-MASS program) plus enhanced education or (2) enhanced education alone. Mindfulness training will consist of a 4-week app-based program starting 1 week prior to surgery, and acupuncture will include up to 8 visits (1 visit prior to surgery and 7 after surgery) during the 13-week program. Enhanced education appropriate for each phase of recovery will be delivered through the mobile app. Primary outcomes are recruitment eligibility and enrollment rates, mindfulness module and acupuncture visit completion rates, questionnaire completion rates, and participant satisfaction. Secondary outcomes include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, sleep disturbance, fear avoidance beliefs, pain intensity, pain medication use, adverse events, hospital readmissions, and emergency department visits. Results: Trial enrollment began in August 2024. As of May 9, 2025, 35 participants have been enrolled. Data analysis has not yet been performed. Enrollment is expected to be completed in the fall of 2025. Conclusions: The I-MASS program addresses the need for mind and body treatments to improve recovery and reduce the risk of persistent pain and opioid use after spine surgery. This integrated model of care is designed to be user-friendly and scalable, enhancing its potential for implementation in real-world settings. A future pragmatic trial is planned to determine if the I-MASS program results in better outcomes compared to either treatment alone or usual care.

  • Open Access

    The Association Between Sociodemographic Factors and Patient Portal Utilization Across Orthopaedic Subspecialties

    by Lauren J. Seo, Alissa M. Arango, Dana G. Rowe, Emily Poehlein, Cynthia Green, C. Rory Goodwin, Melissa M. Erickson

    Background: Patient portal (PP) usage enhances patient engagement, quality of care, and clinical outcomes. However, effective utilization requires digital literacy and internet access, resulting in disparities, particularly among older, non-White, uninsured, or publicly insured patients. While prior studies have examined PP use in specific orthopaedic subspecialties, comprehensive analyses are limited. The aim of this study was to identify social determinants of health of interest (SDOH) associated with PP utilization across orthopaedic subspecialties and to assess its association with outcomes. Methods: A retrospective cohort study of adult patients who underwent orthopaedic procedures was conducted between January 2021 and December 2022. The study included 33,143 encounters involving 28,028 patients. PP utilization was defined as activating and using the PP at least once. SDOH assessed included age, sex, race, ethnicity, language, domestic partnership status, employment status, insurance, and urbanicity. Clinical outcomes included hospital length of stay, 30-day return to the emergency department (ED), 30-day readmission, and discharge disposition. Univariable and multivariable models evaluated associations between SDOH and PP use, while mixed-effects models assessed the association between PP utilization and outcomes. Results: PP utilization varied across subspecialties, with the highest rates in sports medicine (93.9%) and hip preservation (92.6%) and the lowest in trauma (71.7%). Lower odds of PP use were observed among patients older than 65 years, male, non-White, non-English speaking, single, unemployed, uninsured or publicly insured, and those living in rural areas. A decrease of 1 SDOH was associated with a 2.21-fold increase in PP use (odds ratio [OR]): 2.21; 95% confidence interval [CI]: 2.14-2.29; p < 0.001). Nonusers had higher odds of 30-day ED return (OR: 1.73; 95% CI: 1.51-1.99), 30-day readmission (OR: 2.49; 95% CI: 2.12-2.93), nonhome discharge (OR: 4.63, 95% CI: 3.76-5.70), and experienced longer hospital stays (Rate Ratio: 1.61; 95% CI: 1.52-1.70). Conclusions: PP utilization in orthopaedic surgery is associated with social determinants of health and varies by subspecialty. PP nonusage is associated with worse clinical outcomes, highlighting the need for targeted interventions to improve PP adoption among at-risk populations and reduce disparities in orthopaedic care. Level of Evidence: Level III . See Instructions for Authors for a complete description of levels of evidence.

  • Open Access

    Referral, enrollment, and health care use in a comprehensive patient-centered management program for osteoarthritis of the hip and knee

    by Trevor A. Lentz, Preston Roundy, Emily Poehlein, Cynthia L. Green, Richard C. Mather, William Jiranek


  • Open Access

    Mid- to Long-Term Outcomes of the STAR Total Ankle Replacement

    by Albert T. Anastasio, Emily Poehlein, Mark Easley, James A. Nunley

    Category: Ankle Arthritis; Ankle Introduction/Purpose: The Scandinavian Total Ankle Replacement (STAR) is a widely used ankle prosthesis, but mid- to long-term follow up remains limited. In thirteen different studies involving 939 STAR total ankle prostheses, the average duration of follow- up for recipients was 3.9 years. Thus, we sought to evaluate the STAR at the mid- to long-term interval with regards to survivorship, complications, and patient reported outcomes (PROs) in one of the largest series with the longest-term follow up to date. Methods: All patients managed with a primary STAR prosthesis at our institution from March 2002 through January 2017 were included in the analysis. Demographic characteristics including gender, race, age, diabetes status, body mass index (BMI), smoking status, American Society of Anesthesiologist (ASA) score, and surgery time were summarized. The cumulative incidence of implant failure was at 5 years and the last recorded time to event (8 years) were reported with 95% confidence intervals (CI). Paired t- tests were used to compare pre-operative and 5 year post-operative (±1 year) for PROs including Visual Analog Scale (VAS), Short Musculoskeletal Function Assessment (SMFA), Short-form-36 (SF-36), and American Orthopaedic Foot & Ankle Society (AOFAS) hindfoot subscales. Additionally, intra- and post-operative complications were recorded. All statistical analysis were conducted in SAS 9.4 (Cary, NC). Statistical significance was assessed at α = 0.05. Results: 247 patients with a unilateral STAR procedure were included in this analysis. Demographics are listed in Table 1. The average number of years of follow-up was 5.71 ± 4.07 years. The cumulative incidence of implant failure at 5 years was 7.7% (95% CI 4.3%-12.5%). The last failure event occurred at 8 years post-implant. The cumulative incidence of implant failure at 8 years was 11.1% (95% CI 6.3%-17.3%) (Table 2, Figure 1). The most common post-operative complications were impingement (N = 39, 15.8%), ankle pain (N = 22, 8.9%), and implant failure (N = 16, 6.5%) (Table 3). With regards to PROs, patients significantly improved between baseline and 5-year follow up in all measures (all p< 0.001; Table 4). Conclusion: At mid- to long-term follow up, patients receiving the STAR prosthesis experienced a significant and durable improvement in PROs across multiple functional indices. Complication and failure rates were lower than those reported in previous series evaluating the STAR, with an observed survivorship of 88.9% at 8-year follow up.

  • Relevance of cleft palatal width in short-term otologic outcomes

    by H.L. Martin, E.R. Poehlein, A.C. Allori, J.R. Marcus, J. Cheng, H. Lee, E.M. Raynor


  • Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer

    by Sarah E. Burnette, Emily Poehlein, Hui-Jie Lee, Jeremy Force, Kelly Westbrook, Heather N. Moore

    Purpose SOLAR-1 investigated alpelisib-fulvestrant (ALP + FLV) in patients with HR + /HER2-, PIK3CA-mutated advanced breast cancer and demonstrated a clinically significant increase in all-grade and grade (G) 3-4 hyperglycemia (HG) compared to placebo-fulvestrant. Given high rates of HG, a preventative protocol and identification of associated risk factors was implemented. Methods This single-center, retrospective study included patients receiving ALP + FLV. One week before ALP initiation, patients started an insulin-sensitizer. Patients had fasting plasma glucose (FPG) levels drawn day 8, 15, 28, then monthly. Primary outcome was incidence of G2-4 HG by day 28. Risk factors assessed included age, BMI, FPG, and HbA1c. Number of risk factors were compared between patients with and without HG. Results Sixteen women were included with median age of 59 years. The cohort was 69% White, 25% Black, 75% with BMI ≥ 25 kg/m2, and 50% with history of diabetes. By day 28, 9 patients (56%) had G2-4 HG, with only 3 (19%) G3 and zero G4. Patients with G2-4 HG had a median of 2 risk factors compared to only 1 if no HG (p = 0.03). 5 patients (31%) required a temporary hold of ALP and 3 (19%) required dose reduction due to HG. 13 patients permanently discontinued ALP—9 due to disease progression and 4 from an adverse event (only 1 HG). Conclusion Implementation of a HG prophylaxis protocol with ALP in a single-center study demonstrated fewer G3-4 HG events compared to that seen in SOLAR-1 (19% vs 36.6%). An increase in HG-associated risk factors correlated with a higher incidence of G2-4 HG.


  • Open Access

    Abstract 12 Phase I Study of Cord Tissue Derived Mesenchymal Stromal Cells in COVID-19–Related Acute Respiratory Distress Syndrome

    by Bryan Kraft, Linda Brown, Margaret Scott, Frank Vrionis, Ralph Palumbo, Jesse Troy, Emily Poehlein, Lynn Cheatham, Lingye Chen, Joanne Kurtzberg, et al.

    SARS-CoV-2 infection results in the COVID-19 disease that caused a global pandemic. In severe cases, COVID-19 leads to acute respiratory distress syndrome (ARDS), due to direct lung injury and hyperinflammatory response. COVID-related ARDS treatment now includes remdesivir, dexamethasone, and anti-inflammatory monoclonal antibodies, which have decreased the mortality rate, yet patients continue to die from sepsis or multiorgan failure and new treatments are needed. The use of mesenchymal stromal cells (MSC) offers a unique therapeutic option that may shorten time to lung injury resolution through anti-inflammatory, immune-modulatory, and regenerative mechanisms. The aim of this study was to test the safety of human cord tissue-derived MSCs (hCT-MSC) in patients with COVID-related ARDS. This study was funded by The Marcus Foundation. In this phase I multisite study, 10 adults with COVID- related ARDS were treated with 3 daily intravenous infusions of hCT-MSCs (1 million cells/kg/dose, maximum dose 100 million cells with a post thaw viability ≥70%). Patients were excluded if they had evidence of multiorgan failure, immunodeficiency, or were receiving extracorporeal membrane oxygenation or not expected to survive more than 24 hours. The primary endpoint was short-term safety of hCT-MSC infusions. The secondary endpoints included 28-day survival and changes in the Murray Lung Injury Score. From August to November 2020, 10 patients (7 females, 3 males; 2 Black, 6 White, 2 other; 3 Hispanic or Latino), with a median age of 61.5 years (range 39-97), were enrolled at 2 sites. There were no infusion-related or study-related adverse events. The average cell dose administered was 0.94 ± 0.29 cells/kg, and average cell viability was 85% ± 11%; 5 of 30 (17%) doses were less than the study dose, and 29 of 30 (97%) met the ≥70% viability criteria. There were 28 non-serious adverse events in 3 unique patients and 2 serious adverse events in 2 unique patients, which were expected and deemed unrelated to the study product. Five patients died: 3 by day 28 and 2 by day 90. All deaths were determined to be unrelated to the hCT-MSCs. The Murray Lung Injury Score did not appear to change over the 28-day study period. hCT-MSCs infusions are safe in patients with COVID-related ARDS. Future studies determining their efficacy are warranted.

  • SARS-CoV-2 pandemic in New York metropolitan area: the view from a major urgent care provider

    by Madhura S. Rane, Angela Profeta, Emily Poehlein, Sarah Kulkarni, McKaylee Robertson, Chris Gainus, Ashish Parikh, Kerry LeBenger, Daniel Frogel, Denis Nash